Explore 3 Stock Ideas & Industry Insights Download Free Report

Accustem Sciences Inc

Company price
0.118 USD 0.00(0%)
Last update at 2026-11-16T21:00:00Z
VOLUME
5
Market Cap
2.09M

Momentum Score

…

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.12
Low
0.13
High
52 Week Price Range
0.13
Low
1.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
0.10M
Revenue Per Share
0.01
Gross Profit TTM
0.10M
Debt / Equity
-
ROE
-1794.16%
Net Debt
0.01M
ROCE
51.63%
Diluted EPS TTM
-0.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.76M -1.51M -2.05M - -
Net income -1.76M -1.51M -2.05M - -
Selling general administrative 1.48M 1.37M 1.91M - -
Reconciled depreciation 0.00M 0.00M 0.00M - -
Ebit - - - -3.75M -0.67M
Operating income -1.76M -1.51M -2.05M - -
Tax provision 0.00M 0.00M 0.00M - -
Total revenue 0.00M 0.00M 0.00M - -
Total operating expenses 1.76M 1.51M 2.05M - -
Net income from continuing ops -1.76M -1.51M -2.05M - -
Net income applicable to common shares - - - -3.75M -0.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1.55M 0.05M 0.13M - -
Other current assets - - - 0.03M -
Total liab 4.95M 3.36M 2.25M - -
Total stockholder equity -3.40M -3.31M -2.11M - -
Other current liab - - - 0.14M 0.19M
Common stock - - - 0.01M 0.01M
Capital stock 0.02M 0.01M 0.01M - -
Retained earnings -9.78M -8.03M -6.52M -4.47M -0.72M
Cash 0.01M 0.01M 0.02M - -
Total current liabilities 4.95M 3.36M 2.25M 1.08M 0.70M
Net debt 0.01M 0.02M 0.03M - -
Short long term debt 0.02M 0.03M 0.06M - -
Other stockholder equity - - - - -0.14M
Property plant equipment - - - 0.01M -
Total current assets 0.05M 0.05M 0.13M 0.93M 1.35M
Net tangible assets - - - -0.14M 0.65M
Net receivables - - - - 1.35M
Accounts payable 0.70M 0.80M 0.58M 0.31M 0.39M
Non currrent assets other 1.50M - - - -
Non current assets total 1.50M 0.00M 0.00M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M - -
Change to liabilities - - - -0.08M 0.39M
Total cashflows from investing activities - - - -0.01M -0.01M
Net borrowings -0.10M -0.13M -0.34M -0.34M -0.34M
Total cash from financing activities 0.86M 0.65M 0.90M 2.55M 2.55M
Change to operating activities - - - 0.59M 0.25M
Net income -1.76M -1.51M -2.05M -3.75M -0.67M
Change in cash 0.01M -0.02M -0.71M 0.73M 0.73M
Begin period cash flow 0.01M 0.02M 0.73M - -
End period cash flow 0.01M 0.01M 0.02M - -
Total cash from operating activities -0.85M -0.66M -1.62M -1.81M -1.81M
Issuance of capital stock - 0.00M 0.00M - -
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to account receivables - - - 1.35M 1.35M
Other cashflows from financing activities - - - 0.20M 0.20M
Change to netincome - - - 0.07M 0.02M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.01M
Change in working capital 0.74M 0.53M 0.35M - -
Stock based compensation 0.17M 0.30M 0.08M - -
Free cash flow -0.85M -0.66M -1.62M - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ACUT
Accustem Sciences Inc
-
-%
0.12 - - 21.27 - -1.55
NVO
Novo Nordisk A/S
-1.21
2.90%
40.40 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.15
1.14%
531.64 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.70
0.49%
957.10 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Accustem Sciences Inc

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

5 Penn Plaza, New York, NY, United States, 10001

4

Name Title Year Born
Ms. Wendy Blosser CEO & Director 1966
Mr. Jeff Fensterer Chief Operating Officer 1979
Mr. Joe Flanagan Chief Bus. Officer 1974
Mr. Gabriele Marco Antonio Cerrone M.B.A. Executive Chairman of the Board 1972
Ms. Wendy E. Blosser CEO & Director 1967
Mr. Joe Flanagan Chief Business Officer 1975
Ms. Keeren Shah Chief Financial Officer 1975
Ms. Wendy E. Blosser CEO & Director 1966
Mr. Jeff Fensterer Chief Operating Officer 1980
Mr. Joe Flanagan Chief Business Officer 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…